Docstoc

Biotage Unveils New Fully Automated Microwave Peptide Synthesizer

Document Sample
Biotage Unveils New Fully Automated Microwave Peptide Synthesizer Powered By Docstoc
					     Biotage Unveils New Fully Automated Microwave Peptide
                          Synthesizer
   Biotage® (STO: BIOT), introduced an innovative new synthesis platform for
    peptide researchers at the 2012 European Peptide Symposium in Athens,
                                     Greece.

Uppsala, Sweden, September 25, 2012 -- Biotage® (STO: BIOT), a leading global
supplier of solutions and technology for analytical, medicinal and peptide chemistry,
introduced an innovative new synthesis platform for peptide researchers at the 2012
European Peptide Symposium in Athens, Greece. The Biotage® Initiator+ Alstra is a
fully automated, single channel, programmable microwave peptide synthesizer and is
the latest addition to Biotage's growing family of peptide synthesis platforms.

The Initiator+ Alstra is an ideal tool for peptide chemists synthesizing peptides,
peptoids, PNA and peptidomimetics, including extremely difficult modifications. The
system's inherent flexibility for reagent set-up, makes it a highly effective platform for
both small and large scale synthesis from 5 µmol to 2 mmol. With a working volume
from as low as 0.6 mL, the Initiator+ Alstra is perfectly suited for small scale microwave
peptide synthesis, especially when the use of expensive building blocks is required e.g.
PNA. The system's robotic liquid handler and precise digital syringe pumps reduce
reagent and solvent consumption, thus reducing cost and minimizing waste.

The Initiator+ Alstra is programmable via a large 10" touch screen with drag and drop
functionality for optimizing pre-installed or user defined methods. A built-in wizard
makes programming a synthesis sequence effortless and a calculation table, which is
generated, provides the quantities of reagents required, allowing the user to very
quickly go from an idea to execution.

"Initiator+ Alstra is an extremely simple to use work horse which fills an important gap
in the toolbox of the Peptide researcher. Its state of the art interface, simplicity of
operation, speed, size and price are all optimized to match the increasing demands
which Peptide Chemists are under today", say's Dr. Amit Mehrotra, Peptide Product
Manager at Biotage. "This product is the result of customer input and demands and we
are very excited to now be putting it into their hands".

For further information visit http://www.biotage.com or call:
In Europe: +46 18 56 57 10
In North America: (Toll Free) 1 800 446 4752
In Japan: +81 422 28 1233
Other areas, please call: +46 18 56 57 10.

-Ends-

For further press information at Biotage please contact:
James Churchill
Marketing Communications
Biotage GB Limited
Distribution Way
Dyffryn Business Park
Ystrad Mynach
Hengoed, Wales CF82 7TS
United Kingdom
Tel: +44 (0)1443 811 849
Mobile: +44(0)7875484778
E-Mail: james.churchill@biotage.com

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical and
medicinal chemistry. Customers include the world’s top pharmaceutical and
biotechnology companies, as well as leading academic institutes. The company is
headquartered in Uppsala, Sweden, with offices in China, Japan, the United Kingdom,
the United States and a worldwide network of distributors. Biotage has 272 employees
with sales of 428.9 MSEK in 2010. Biotage is listed on the NASDAQ OMX Nordic Stock
Exchange. Website: http://www.biotage.com.

				
DOCUMENT INFO
Shared By:
Stats:
views:25
posted:9/25/2012
language:English
pages:2
Description: Biotage® (STO: BIOT), introduced an innovative new synthesis platform for peptide researchers at the 2012 European Peptide Symposium in Athens, Greece.